NeuBase Therapeutics Inc
F:O7PA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
NeuBase Therapeutics Inc
EPS (Diluted)
NeuBase Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NeuBase Therapeutics Inc
F:O7PA
|
EPS (Diluted)
-$4
|
CAGR 3-Years
35%
|
CAGR 5-Years
45%
|
CAGR 10-Years
25%
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$1
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
35%
|
CAGR 5-Years
45%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$12
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$14
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$42
|
CAGR 3-Years
-4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
24%
|
|
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
See Also
What is NeuBase Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-5
USD
Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's EPS (Diluted) amounts to -5 USD.
What is NeuBase Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
25%
Over the last year, the EPS (Diluted) growth was 76%. The average annual EPS (Diluted) growth rates for NeuBase Therapeutics Inc have been 35% over the past three years , 45% over the past five years , and 25% over the past ten years .